What did @pattycakesfit actually say?
The short version: he's doing a six-week BPC-157 cycle injected directly into his left knee before an off-season bulk, and he wants you to know it's "100% natural." His argument is that BPC-157 is derived from amino acid sequences found in the stomach, therefore it's naturally occurring, therefore injecting it isn't a departure from nature. He also says doctors prescribe it for tennis elbow, runner's knee, and shoulder injuries, and he plugs Transcend HRT as his source.
He frames this as a "complete breakdown" of his protocol. It's not that, really. He doesn't mention dose, injection frequency, reconstitution, or how he's verifying product quality. But the core claims, the natural argument, the angiogenesis mechanism, the tendon and GI healing applications, are specific enough to fact-check. So let's do that.
Does the science back this up?
The mechanistic science is real. The clinical evidence in humans is thin. That gap matters a lot here.
BPC-157 is a synthetic pentadecapeptide, a 15-amino-acid sequence derived from a protein found in gastric juice. Sikiric et al. have been publishing on it since the 1990s, with animal studies showing accelerated tendon-to-bone healing, reduced inflammation, and yes, angiogenic effects. The angiogenesis claim specifically has support: Chang et al. (2011, Journal of Applied Physiology) found BPC-157 promoted blood vessel formation and improved tendon healing in rat models. That part checks out mechanistically.
The problem is almost all of this research is in rodents. As of 2024, there are no completed, peer-reviewed Phase II or Phase III human clinical trials for BPC-157 in orthopedic applications. The FDA has not approved it. The World Anti-Doping Agency added it to the prohibited list in 2022, which is worth noting for anyone using it in competitive sport.
What did they get wrong (or right)?
He got the mechanism roughly right, and he's wrong about the "natural" framing.
Credit where it's due: angiogenesis promoting new blood vessel growth to aid tissue repair is a real and documented mechanism in the preclinical literature. Saying it helps tendons and ligaments in animal models is not a fabrication. That's an honest summary of what the rodent data shows.
But "100% natural" is where this falls apart. Yes, BPC-157's sequence is derived from a gastric protein. No, that doesn't make injecting a synthesized, reconstituted peptide directly into your knee joint "natural" by any reasonable definition. Insulin is also derived from a human protein sequence. Synthesized compounds modeled on endogenous molecules are still synthesized compounds. The natural argument is a rhetorical move, not a scientific one.
The claim that "doctors prescribe BPC-157" also needs context. In the U.S., it is available through compounding pharmacies under certain circumstances, but it is not FDA-approved and prescribing practices vary significantly. Framing it as routine medical prescription overstates where the clinical consensus actually is.
What should you actually know?
BPC-157 is one of the more biologically plausible peptides circulating in fitness communities right now, and that plausibility is exactly why the lack of human trial data is frustrating rather than dismissible.
If you're considering it, a few things deserve your attention. Source quality is a serious issue. Research-grade and compounding-grade BPC-157 vary widely in purity and concentration, and intra-articular injection of a contaminated or misdosed product carries real infection and inflammatory risk. A 2023 analysis published in Drug Testing and Analysis found significant discrepancies between labeled and actual peptide concentrations in commercially available samples.
The WADA prohibition is also not a minor detail. Anyone subject to drug testing in any sport should know this is on the banned list regardless of how natural it feels to inject.
Finally, the six-week timeline he describes for measurable joint healing is optimistic. Even if the preclinical mechanisms translate to humans, connective tissue remodeling operates on longer timescales than six weeks in most clinical contexts. Managing expectations matters here.